Vanda Pharma (NASDAQ:VNDA) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a high estimate of $18.00, and a low estimate of $18.00. No alteration is observed as the current average remains at the previous average price target.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of Vanda Pharma among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vanda Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Vanda Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Vanda Pharma: A Closer Look

Key Indicators: Vanda Pharma's Financial Health

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

Revenue Growth: Over the 3 months period, Vanda Pharma showcased positive performance, achieving a revenue growth rate of 22.76% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Vanda Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.17%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.98%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Vanda Pharma's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.82% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Vanda Pharma's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.